

CELLTECH GROUP PLC
Form SC TO-T/A
June 10, 2004

[QuickLinks](#) -- Click here to rapidly navigate through this document

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

SCHEDULE TO

(Rule 14d-100)

**TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934**

(Amendment No. 5)

Celltech Group plc

(Name of Subject Company (Issuer))

UCB S.A.

(Names of Filing Persons (Offeror))

**Ordinary Shares
American Depositary Shares**
(Title of Class of Securities)

**Ordinary Shares (GB0001822765)
American Depositary Shares (US1511581027)**
(CUSIP Number of Class of Securities)

**Jettie Van Caenegem
UCB S.A.
60 Allee de la Recherche, 1070
Brussels
Tel: 011 32 2 559 9516**

(Name, Address, and Telephone Number of Person
Authorized to Receive Notices and Communications on Behalf of Filing Persons)

CALCULATION OF FILING FEE

Transaction Valuation(1)

Amount of Filing Fee(1)(2)

\$2,731,955,531

\$346,138

(1)

Edgar Filing: CELLTECH GROUP PLC - Form SC TO-T/A

For purposes of calculating the filing fee pursuant to Rule 0-11(d), the transaction value of the Celltech Shares and Celltech ADSs (each Celltech ADS represents two Celltech Shares) to be received by UCB, assuming acceptance of the Offer by holders in the United States, is calculated as follows: 278,128,673 Celltech Shares (including Celltech Shares represented by ADSs) multiplied by 550 pence per Celltech Share, the cash consideration being offered per Celltech Share which yields £1,543,913,835, converted to U.S. dollars at the noon buying rate on May 17, 2004, of £1=\$1.7695 which yields \$2,731,955,531, multiplied by 0.0001267, which yields \$346,138. Each of the capitalized terms used is defined in the Tender Offer Statement on Schedule TO filed May 19, 2004.

(2)

Sent via wire transfer to the SEC on May 18, 2004.

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:

Filing Party:

Form or Registration No.:

Date Filed:

Check the box if the filing relates solely to preliminary communications made before commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

third-party tender offer subject to Rule 14d-1.

issue tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

Edgar Filing: CELLTECH GROUP PLC - Form SC TO-T/A

This Amendment No. 5 (the "**Amendment**") amends the Tender Offer Statement on Schedule TO initially filed with the Securities and Exchange Commission (the "**SEC**") on May 19, 2004 by UCB S.A., a société anonyme organized under the laws of the Kingdom of Belgium ("**UCB**"), relating to a third-party tender offer (the "**Offer**") by UCB to purchase all of the (i) ordinary shares, nominal value of 50 pence each (the "**Celltech Shares**"), and (ii) American Depositary Shares, each representing two Celltech Shares and evidenced by American Depositary Receipts, of Celltech Group plc, a public limited company organized under the laws of England and Wales ("**Celltech**").

On June 10, 2004, public disclosure pursuant to Rule 8 of the U.K. City Code on Takeovers and Mergers (the "**City Code**") was made in the United Kingdom in connection with the purchase of 2,703,656 Celltech Shares at 548 pence per share by or on behalf of UCB, outside the United States, otherwise than pursuant to the Offer. As at the date of this Amendment, UCB owned 46,014,144 Celltech Shares in aggregate, representing approximately 16.5% of the entire issued share capital of Celltech.

Edgar Filing: CELLTECH GROUP PLC - Form SC TO-T/A

ITEM 12. EXHIBITS.

- 99.(a)(1) Offer Document dated May 19, 2004.
- 99.(a)(2) Letter of Transmittal.
- 99.(a)(3) Notice of Guaranteed Delivery.
- 99.(a)(4) Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
- 99.(a)(5) Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
- 99.(a)(6) Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.
- 99.(a)(7) Summary Advertisement in the *Wall Street Journal*.
- 99.(a)(8) Form of Acceptance, Authority and Election.
- 99.(a)(9) Instructions on "How to accept the Offer for your Celltech Shares".
- 99.(a)(10)* Agreement for the Collaboration Between Celltech R & D LTD and UCB Farchim S.A.
- 99.(a)(11) Confidentiality Agreement dated April 19, 2004 between UCB and Celltech.
- 99.(a)(12) Memorandum of Understanding dated May 13, 2004 between UCB and Celltech.
- 99.(a)(13) Side Letter from UCB to Celltech dated May 17, 2004.
- 99.(a)(14) Summary advertisement in the *Financial Times*.
- 99.(a)(15) Announcement pursuant to Rule 8 of the City Code in connection with an acquisition of Celltech Shares by or for the benefit of UCB.
- 99.(a)(16) Announcement pursuant to Rule 8 of the City Code in connection with an acquisition of Celltech Shares by or for the benefit of UCB.
- 99.(a)(17) Announcement pursuant to Rule 8 of the City Code in connection with an acquisition of Celltech Shares by or for the benefit of UCB.
- 99.(a)(18)^o Announcement pursuant to Rule 8 of the City Code in connection with an acquisition of Celltech Shares by or for the benefit of UCB.
- 99.(b)(1) Umbrella Agreement attaching a Credit Facility Letter, Credit Agreement, General Lending Conditions and General Terms and Conditions, dated as of May 17, 2004, between Fortis Bank S.A./N.V. and UCB S.A.
- 99.(b)(2) Umbrella Agreement attaching a Credit Contract, Credit Conditions and General Conditions, dated as of May 17, 2004, between KBC Bank N.V. and UCB S.A.
- 99.(d)(1) Inducement Agreement dated May 17, 2004 between UCB and Celltech.
- 99.(d)(2) Irrevocable undertaking by Mr. Goran Ando.
- 99.(d)(3) Irrevocable undertaking by Mr. Mick Newmarch.
- 99.(d)(4) Irrevocable undertaking by Ms. Ingelise Saunders.
- 99.(d)(5) Irrevocable undertaking by Ms. Melanie Lee.
- 99.(d)(6) Irrevocable undertaking by Dr. Peter Fellner.
- 99.(d)(7) Irrevocable undertaking by Mr. Peter Read.

Edgar Filing: CELLTECH GROUP PLC - Form SC TO-T/A

- 99.(d)(8) Irrevocable undertaking by Mr. Marvin Jaffe.
- 99.(d)(9) Irrevocable undertaking by Mr. Peter Allen.
- 99.(d)(10) Irrevocable undertaking by Dr. Peter Fellner and Mrs. Jennifer Fellner.
- 99.(d)(11) Irrevocable undertaking by Mrs. Jennifer Fellner.
- 99.(d)(12) Irrevocable undertaking by Ms. Norma Read.
-

*
Confidential treatment requested. Confidential material has been redacted and separately submitted to the SEC.

Previously filed with the SEC.

o
Filed herewith.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

By: /s/ GEORGES JACOBS

Name: Baron Georges Jacobs
Title: Executive Director
Date: June 10, 2004

EXHIBIT INDEX

- 99.(a)(1) Offer Document dated May 19, 2004.
- 99.(a)(2) Letter of Transmittal.
- 99.(a)(3) Notice of Guaranteed Delivery.
- 99.(a)(4) Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
- 99.(a)(5) Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
- 99.(a)(6) Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.
- 99.(a)(7) Summary Advertisement in the *Wall Street Journal*.
- 99.(a)(8) Form of Acceptance, Authority and Election.
- 99.(a)(9) Instructions on "How to accept the Offer for your Celltech Shares".
- 99.(a)(10)* Agreement for the Collaboration Between Celltech R & D LTD and UCB Farchim S.A.
- 99.(a)(11) Confidentiality Agreement dated April 19, 2004 between UCB and Celltech.
- 99.(a)(12) Memorandum of Understanding dated May 13, 2004 between UCB and Celltech.
- 99.(a)(13) Side Letter from UCB to Celltech dated May 17, 2004.
- 99.(a)(14) Summary advertisement in the *Financial Times*.
- 99.(a)(15) Announcement pursuant to Rule 8 of the City Code in connection with an acquisition of Celltech Shares by or for the benefit of UCB.
- 99.(a)(16) Announcement pursuant to Rule 8 of the City Code in connection with an acquisition of Celltech Shares by or for the benefit of UCB.
- 99.(a)(17) Announcement pursuant to Rule 8 of the City Code in connection with an acquisition of Celltech Shares by or for the benefit of UCB.
- 99.(a)(18)^o Announcement pursuant to Rule 8 of the City Code in connection with an acquisition of Celltech Shares by or for the benefit of UCB.
- 99.(b)(1) Umbrella Agreement attaching a Credit Facility Letter, Credit Agreement, General Lending Conditions and General Terms and Conditions, dated as of May 17, 2004, between Fortis Bank S.A./N.V. and UCB S.A.
- 99.(b)(2) Umbrella Agreement attaching a Credit Contract, Credit Conditions and General Conditions, dated as of May 17, 2004, between KBC Bank N.V. and UCB S.A.
- 99.(d)(1) Inducement Agreement dated May 17, 2004 between UCB and Celltech.
- 99.(d)(2) Irrevocable undertaking by Mr. Goran Ando.
- 99.(d)(3) Irrevocable undertaking by Mr. Mick Newmarch.
- 99.(d)(4) Irrevocable undertaking by Ms. Ingelise Saunders.
- 99.(d)(5) Irrevocable undertaking by Ms. Melanie Lee.
- 99.(d)(6) Irrevocable undertaking by Dr. Peter Fellner.

Edgar Filing: CELLTECH GROUP PLC - Form SC TO-T/A

- 99.(d)(7) Irrevocable undertaking by Mr. Peter Read.
 - 99.(d)(8) Irrevocable undertaking by Mr. Marvin Jaffe.
 - 99.(d)(9) Irrevocable undertaking by Mr. Peter Allen.
 - 99.(d)(10) Irrevocable undertaking by Dr. Peter Fellner and Mrs. Jennifer Fellner.
 - 99.(d)(11) Irrevocable undertaking by Mrs. Jennifer Fellner.
-

99.(d)(12) Irrevocable undertaking by Ms. Norma Read.

*

Confidential treatment requested. Confidential material has been redacted and separately submitted to the SEC.

Previously filed with the SEC.

o

Filed herewith.

QuickLinks

SIGNATURE

EXHIBIT INDEX